Published in Trans R Soc Trop Med Hyg on October 09, 2006
Vivax malaria: neglected and not benign. Am J Trop Med Hyg (2007) 10.16
Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med (2008) 6.61
Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev (2011) 5.15
Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet (2007) 4.85
Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis (2014) 4.09
Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev (2009) 3.41
Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis (2007) 3.27
Artemisinin combination therapy for vivax malaria. Lancet Infect Dis (2010) 3.08
Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar-capillary inflammation. J Infect Dis (2007) 3.02
Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis (2008) 3.01
Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob Agents Chemother (2008) 2.77
Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS One (2007) 2.66
Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum. Malar J (2008) 2.41
Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis (2009) 2.15
Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother (2007) 2.02
Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax. J Infect Dis (2008) 1.96
Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes. Antimicrob Agents Chemother (2008) 1.86
Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria. J Infect Dis (2009) 1.86
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax. Antimicrob Agents Chemother (2010) 1.70
Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob Agents Chemother (2007) 1.64
Malaria distribution, prevalence, drug resistance and control in Indonesia. Adv Parasitol (2011) 1.61
Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog (2009) 1.46
Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome. PLoS Pathog (2010) 1.37
Drug resistance and genetic mapping in Plasmodium falciparum. Curr Genet (2008) 1.36
Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Malar J (2010) 1.35
Coma associated with microscopy-diagnosed Plasmodium vivax: a prospective study in Papua, Indonesia. PLoS Negl Trop Dis (2011) 1.23
Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax. Trends Parasitol (2012) 1.17
Plasmodium vivax treatments: what are we looking for? Curr Opin Infect Dis (2011) 1.16
KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. Antimicrob Agents Chemother (2014) 1.14
Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India. Malar J (2015) 1.13
Comparative ex vivo activity of novel endoperoxides in multidrug-resistant plasmodium falciparum and P. vivax. Antimicrob Agents Chemother (2012) 1.09
Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy. PLoS One (2014) 1.08
In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia. PLoS One (2013) 1.06
Contrasting Transmission Dynamics of Co-endemic Plasmodium vivax and P. falciparum: Implications for Malaria Control and Elimination. PLoS Negl Trop Dis (2015) 1.04
In vivo therapeutic efficacy of chloroquine alone or in combination with primaquine against vivax malaria in Kolkata, West Bengal, India, and polymorphism in pvmdr1 and pvcrt-o genes. Antimicrob Agents Chemother (2012) 1.03
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax. Antimicrob Agents Chemother (2008) 1.03
In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia. Antimicrob Agents Chemother (2010) 1.02
Clinico-laboratory profile of severe Plasmodium vivax malaria in a tertiary care centre in Kolkata. Trop Parasitol (2013) 1.02
Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia. Malar J (2010) 1.01
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax. Antimicrob Agents Chemother (2010) 0.99
Highly effective therapy for maternal malaria associated with a lower risk of vertical transmission. J Infect Dis (2011) 0.98
Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P. vivax. Antimicrob Agents Chemother (2011) 0.96
Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review. Malar J (2014) 0.95
Apoptosis and dysfunction of blood dendritic cells in patients with falciparum and vivax malaria. J Exp Med (2013) 0.94
Global Epidemiology of Plasmodium vivax. Am J Trop Med Hyg (2016) 0.93
Research challenges and gaps in malaria knowledge in Papua New Guinea. Acta Trop (2011) 0.92
Plasmodium vivax susceptibility to ferroquine. Antimicrob Agents Chemother (2010) 0.89
Management of relapsing Plasmodium vivax malaria. Expert Rev Anti Infect Ther (2016) 0.88
Plasmodium malariae Infection Associated with a High Burden of Anemia: A Hospital-Based Surveillance Study. PLoS Negl Trop Dis (2015) 0.86
Quantification of Plasmodium ex vivo drug susceptibility by flow cytometry. Malar J (2015) 0.85
Expression of Plasmodium vivax crt-o Is Related to Parasite Stage but Not Ex Vivo Chloroquine Susceptibility. Antimicrob Agents Chemother (2015) 0.84
Plasmodium vivax and Plasmodium falciparum ex vivo susceptibility to anti-malarials and gene characterization in Rondônia, West Amazon, Brazil. Malar J (2014) 0.84
Severe congenital malaria acquired in utero. Am J Trop Med Hyg (2010) 0.82
Age-related susceptibility to severe malaria associated with galectin-2 in highland Papuans. J Infect Dis (2010) 0.82
Functional analysis of Plasmodium vivax dihydrofolate reductase-thymidylate synthase genes through stable transformation of Plasmodium falciparum. PLoS One (2012) 0.82
Potent Ex Vivo Activity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparum and Plasmodium vivax. Antimicrob Agents Chemother (2015) 0.81
Next-Generation Sequencing of Plasmodium vivax Patient Samples Shows Evidence of Direct Evolution in Drug-Resistance Genes. ACS Infect Dis (2015) 0.80
Efficacy of Artesunate-mefloquine for Chloroquine-resistant Plasmodium vivax Malaria in Malaysia: An Open-label, Randomized, Controlled Trial. Clin Infect Dis (2016) 0.79
Human T cell recognition of the blood stage antigen Plasmodium hypoxanthine guanine xanthine phosphoribosyl transferase (HGXPRT) in acute malaria. Malar J (2009) 0.79
Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia. Malar J (2015) 0.79
Monitoring of failure of chloroquine treatment for Plasmodium vivax using polymerase chain reaction in Sanliurfa province, Turkey. Parasitol Res (2010) 0.78
A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria. ACS Infect Dis (2016) 0.78
Asymptomatic Vivax and Falciparum Parasitaemia with Helminth Co-Infection: Major Risk Factors for Anaemia in Early Life. PLoS One (2016) 0.77
Epidemiology of Plasmodium vivax in Indonesia. Am J Trop Med Hyg (2016) 0.75
Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling. PLoS Med (2016) 0.75
Treatment-seeking behaviour and associated costs for malaria in Papua, Indonesia. Malar J (2016) 0.75
Population pharmacokinetics of a three-day chloroquine treatment in patients with Plasmodium vivax infection on the Thai-Myanmar border. Malar J (2016) 0.75
Diagnosis and Treatment of Plasmodium vivax Malaria. Am J Trop Med Hyg (2016) 0.75
Treatment policy change to dihydroartemisinin-piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes. Malar J (2015) 0.75
Plasmodium falciparum and P. vivax demonstrate contrasting chloroquine resistance reversal phenotypes. Antimicrob Agents Chemother (2017) 0.75
The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature (2005) 31.73
Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. Am J Trop Med Hyg (1999) 4.60
Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother (2004) 4.54
Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg (1997) 3.61
Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother (2000) 3.46
The assessment of antimalarial drug efficacy. Trends Parasitol (2002) 3.38
Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg (1991) 3.31
Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother (2002) 2.52
Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg (2003) 2.49
Determination of chloroquine and its desethyl metabolite in plasma, red blood cells and urine by liquid chromatography. J Chromatogr (1982) 2.40
Can primaquine therapy for vivax malaria be improved? Trends Parasitol (2003) 2.31
Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet (1993) 2.23
Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis (1995) 1.87
Chloroquine-resistant Plasmodium vivax in transmigration settlements of West Kalimantan, Indonesia. Am J Trop Med Hyg (1998) 1.82
Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. Trans R Soc Trop Med Hyg (1996) 1.76
In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium falciparum at Nabire, Irian Jaya, Indonesia. Am J Trop Med Hyg (1997) 1.74
Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria. Antimicrob Agents Chemother (2000) 1.52
Open comparison of intramuscular chloroquine and quinine in children with severe chloroquine-sensitive falciparum malaria. Lancet (1989) 1.50
Malaria situation in several villages around Timika, south central Irian Jaya, Indonesia. Southeast Asian J Trop Med Public Health (1998) 1.42
Artesunate and mefloquine in the treatment of uncomplicated multidrug-resistant hyperparasitaemic falciparum malaria. Trans R Soc Trop Med Hyg (1998) 1.36
Higher gametocyte prevalence following failure of treatment of Plasmodium falciparum malaria with sulfadoxine-pyrimethamine and the combination of chloroquine plus sulfadoxine-pyrimethamine: implications for progression of anti-folate resistance. Trans R Soc Trop Med Hyg (2002) 1.33
Vector studies and epidemiology of malaria in Irian Jaya, Indonesia. Southeast Asian J Trop Med Public Health (1980) 1.31
Chloroquine/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya, Indonesia. Am J Trop Med Hyg (2001) 1.22
Therapy of uncomplicated falciparum malaria: a randomized trial comparing artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in Irian Jaya, Indonesia. Am J Trop Med Hyg (2001) 1.17
Preliminary survey for chloroquine resistant malaria in parts of North Sumatra, Indonesia. Southeast Asian J Trop Med Public Health (1974) 0.86
Common west African HLA antigens are associated with protection from severe malaria. Nature (1991) 9.43
Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet (2000) 7.06
Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis (2000) 6.06
Maternal antibodies block malaria. Nature (1998) 5.67
Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet (1993) 5.11
Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet (2007) 4.85
The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob Agents Chemother (1999) 4.64
Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg (2000) 4.63
Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial. Am J Med (1993) 4.41
Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis (2007) 3.27
The epidemiology of melioidosis in Australia and Papua New Guinea. Acta Trop (2000) 3.16
Field evaluation of the ICT malaria P.f/P.v immunochromatographic test for detection of Plasmodium falciparum and Plasmodium vivax in patients with a presumptive clinical diagnosis of malaria in eastern Indonesia. J Clin Microbiol (1999) 3.05
Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg (1999) 2.98
Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob Agents Chemother (2008) 2.77
Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg (2000) 2.76
Melioidosis: acute and chronic disease, relapse and re-activation. Trans R Soc Trop Med Hyg (2000) 2.71
Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrob Agents Chemother (1998) 2.61
Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother (2000) 2.54
A cluster of melioidosis cases from an endemic region is clonal and is linked to the water supply using molecular typing of Burkholderia pseudomallei isolates. Am J Trop Med Hyg (2001) 2.54
High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J Infect Dis (1992) 2.21
Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother (2007) 2.02
Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax. J Infect Dis (2008) 1.96
Persistent ICT malaria P.f/P.v panmalarial and HRP2 antigen reactivity after treatment of Plasmodium falciparum malaria is associated with gametocytemia and results in false-positive diagnoses of Plasmodium vivax in convalescence. J Clin Microbiol (2001) 1.96
Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1997) 1.95
HLA class I typing by PCR: HLA-B27 and an African B27 subtype. Lancet (1991) 1.86
Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg (1996) 1.85
Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. Trans R Soc Trop Med Hyg (1996) 1.76
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax. Antimicrob Agents Chemother (2010) 1.70
A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health (2007) 1.61
New antimalarials. A risk-benefit analysis. Drug Saf (1995) 1.60
Transmission intensity and Plasmodium falciparum diversity on the northwestern border of Thailand. Am J Trop Med Hyg (1998) 1.54
Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis (1999) 1.49
Neurological melioidosis: seven cases from the Northern Territory of Australia. Clin Infect Dis (1992) 1.43
Cost-effectiveness of artesunate for the treatment of severe malaria. Trop Med Int Health (2009) 1.43
A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg (2000) 1.43
Failure of the 'pan-malarial' antibody of the ICT Malaria P.f/P.v immunochromatographic test to detect symptomatic Plasmodium malariae infection. Trans R Soc Trop Med Hyg (2000) 1.41
Mefloquine in infants and young children. Ann Trop Paediatr (1996) 1.34
Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg (2002) 1.33
Assessment of pfmdr 1 gene copy number by tandem competitive polymerase chain reaction. Mol Biochem Parasitol (1997) 1.29
Artesunate versus artemether for the treatment of recrudescent multidrug-resistant falciparum malaria. Am J Trop Med Hyg (1998) 1.29
Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum. Antimicrob Agents Chemother (2008) 1.26
Storage duration and polymerase chain reaction detection of Plasmodium falciparum from blood spots on filter paper. Am J Trop Med Hyg (2003) 1.24
The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. Eur J Clin Pharmacol (2003) 1.24
Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration. Antimicrob Agents Chemother (2005) 1.21
Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg (2001) 1.20
Extensive genetic diversity in the HLA class II region of Africans, with a focally predominant allele, DRB1*1304. Proc Natl Acad Sci U S A (1992) 1.20
Pulmonary tuberculosis, impaired lung function, disability and quality of life in a high-burden setting. Int J Tuberc Lung Dis (2009) 1.20
Therapy of uncomplicated falciparum malaria: a randomized trial comparing artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in Irian Jaya, Indonesia. Am J Trop Med Hyg (2001) 1.17
Two patients with falciparum malaria and poor in vivo responses to artesunate. Trans R Soc Trop Med Hyg (1999) 1.17
Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur J Clin Pharmacol (2003) 1.15
Measuring nitric oxide production in human clinical studies. Methods Enzymol (1999) 1.13
A protocol system to satisfy research specific, disease specific, physician specific, and patient specific informational needs. Proc Annu Symp Comput Appl Med Care (1992) 1.12
An alternative method for sputum storage and transport for mycobacterium tuberculosis drug resistance surveys. Int J Tuberc Lung Dis (2006) 1.12
A promoter polymorphism in the gene encoding interleukin-12 p40 (IL12B) is associated with mortality from cerebral malaria and with reduced nitric oxide production. Genes Immun (2002) 1.07
Detection of histidine rich protein 2 and panmalarial ICT Malaria Pf/Pv test antigens after chloroquine treatment of uncomplicated falciparum malaria does not reliably predict treatment outcome in eastern Indonesia. Am J Trop Med Hyg (2001) 1.07
Glycosylphosphatidylinositols in malaria pathogenesis and immunity: potential for therapeutic inhibition and vaccination. Curr Top Microbiol Immunol (2005) 1.05
The chromosomal organization of the Plasmodium falciparum var gene family is conserved. Mol Biochem Parasitol (1997) 1.05
The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific. Trans R Soc Trop Med Hyg (2008) 1.04
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax. Antimicrob Agents Chemother (2008) 1.03
In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia. Antimicrob Agents Chemother (2010) 1.02